Overview

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Status:
Terminated

Trial end date:
2020-03-13

Target enrollment:

Participant gender:

Summary

This Phase IV, multicenter study will evaluate whether participants with Hemophilia A (PwHA) with or without inhibitors receiving emicizumab prophylaxis can safely undergo minor surgical procedures without additional prophylactic bypassing agents (BPA; for participants with inhibitors) or factor VIII (FVIII; for participants without inhibitors).

Phase:

Phase 4

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies, Bispecific
Factor VIII